IP Library Granted Patent US 10,039,515
Granted Patent B2
US 10,039,515 · App. 15/263,767 · Granted Aug 7, 2018

Methods for treating idiopathic pulmonary fibrosis

Inventors: Seth Porter (San Carlos, CA); John L Stauffer (Cupertino, CA)
Assignee: FIBROGEN, INC.
A61B6/5217A61B6/032A61B6/50A61K49/0004C07K16/22A61K2039/505
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,039,515
App. No.
15/263,767
Granted
Aug 7, 2018
Kind
B2
Abstract

The present invention relates to methods and medicaments useful for treating idiopathic pulmonary fibrosis (IPF) by administering anti-CTGF antibodies. Methods for prognosing individuals with IPF are also provided.

Claims (7)

1. A method for treating idiopathic pulmonary fibrosis (IPF) in a subject in need thereof, the method comprising:

(a) taking a baseline measurement of a pulmonary radiographic parameter, wherein the pulmonary radiographic parameter is fibrosis;

(b) administering at least 15 mg/kg of an anti-CTGF antibody every three weeks, thereby stabilizing or producing at least a 2% reduction in fibrosis compared to the baseline measurement, wherein the anti-CTGF antibody is identical to the antibody produced by the cell line identified by ATCC Accession No. PTA-6006.

2. The method of claim 1 wherein administration of the anti-CTGF antibody also stabilizes or produces at least a 2% redaction, compared to a baseline measurement, in a pulmonary radiographic parameter selected from the group consisting of ground glass opacity and honeycomb formation.

3. The method of claim 1 , wherein the subject has a forced vital capacity percent (FVC %) predicted of greater than about 55% prior to treatment with the anti-CTGF antibody.

4. The method of claim 1 , wherein the subject has less than 50% parenchymal fibrosis prior to treatment with the anti-CTGF antibody.

5. The method of claim 1 , wherein the subject has less than 25% honeycombing within the whole lung prior to treatment the anti-CTGF antibody.

Assignments (3)
RELEASE OF SECURITY INTEREST Recorded Sep 3, 2025
From: WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT
To: FIBROGEN, INC.
Reel/Frame 072785/0760 →
SECURITY INTEREST Recorded May 1, 2023
From: FIBROGEN, INC.
To: WILMINGTON TRUST, NATIONAL ASSOCIATION
Reel/Frame 063504/0221 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 17, 2018
From: PORTER, SETH; STAUFFER, JOHN L
To: FIBROGEN, INC.
Reel/Frame 046370/0839 →
Continuity (3)
Continuation 14398380
Provisional Application 61642366 · May 3, 2012
Related Publication 20170027535A1 · Feb 2, 2017